489 related articles for article (PubMed ID: 20067838)
1. Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation.
Flomenberg N; Comenzo RL; Badel K; Calandra G
Biol Blood Marrow Transplant; 2010 May; 16(5):695-700. PubMed ID: 20067838
[TBL] [Abstract][Full Text] [Related]
2. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
Steinberg M; Silva M
Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
[TBL] [Abstract][Full Text] [Related]
3. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.
Stewart DA; Smith C; MacFarland R; Calandra G
Biol Blood Marrow Transplant; 2009 Jan; 15(1):39-46. PubMed ID: 19135941
[TBL] [Abstract][Full Text] [Related]
5. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
[TBL] [Abstract][Full Text] [Related]
6. FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation.
Brave M; Farrell A; Ching Lin S; Ocheltree T; Pope Miksinski S; Lee SL; Saber H; Fourie J; Tornoe C; Booth B; Yuan W; He K; Justice R; Pazdur R
Oncology; 2010; 78(3-4):282-8. PubMed ID: 20530974
[TBL] [Abstract][Full Text] [Related]
7. Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial.
Russell N; Douglas K; Ho AD; Mohty M; Carlson K; Ossenkoppele GJ; Milone G; Pareja MO; Shaheen D; Willemsen A; Whitaker N; Chabannon C
Haematologica; 2013 Feb; 98(2):172-8. PubMed ID: 22983579
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.
Li J; Hamilton E; Vaughn L; Graiser M; Renfroe H; Lechowicz MJ; Langston A; Prichard JM; Anderson D; Gleason C; Lonial S; Flowers CR; Kaufman JL; Waller EK
Transfusion; 2011 Oct; 51(10):2175-82. PubMed ID: 21492180
[TBL] [Abstract][Full Text] [Related]
9. Plerixafor dosing and administration in a patient with dialysis-dependent renal failure.
Gregory KM; Rao KV; Armistead PM
Ann Pharmacother; 2010 Dec; 44(12):2028-30. PubMed ID: 21098756
[TBL] [Abstract][Full Text] [Related]
10. Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma.
Harvey RD; Kaufman JL; Johnson HR; Nooka A; Vaughn L; Flowers CR; Khoury HJ; Lechowicz MJ; Langston AA; Lonial S; Waller EK
Biol Blood Marrow Transplant; 2013 Sep; 19(9):1393-5. PubMed ID: 23764455
[TBL] [Abstract][Full Text] [Related]
11. Patients' outcome after rescue plerixafor administration for autologous stem cell mobilization: a single-center retrospective analysis.
Spoerl S; Peter R; Wäscher D; Götze K; Verbeek M; Peschel C; Krackhardt AM
Transfusion; 2017 Jan; 57(1):115-121. PubMed ID: 27859332
[TBL] [Abstract][Full Text] [Related]
12. A Pilot, Exploratory, Randomized, Phase II Safety Study Evaluating Tumor Cell Mobilization and Apheresis Product Contamination in Patients Treated with Granulocyte Colony-Stimulating Factor Alone or Plus Plerixafor.
Nahi H; Celanovic M; Liu Q; Lund J; Peceliunas V
Biol Blood Marrow Transplant; 2019 Jan; 25(1):34-40. PubMed ID: 30149148
[TBL] [Abstract][Full Text] [Related]
13. Stimulation of adrenergic activity by desipramine enhances hematopoietic stem and progenitor cell mobilization along with G-CSF in multiple myeloma: A pilot study.
Shastri A; Budhathoki A; Barta SK; Kornblum N; Derman O; Battini R; Raghupathy R; Verma AK; Frenette PS; Braunschweig I; Janakiram M
Am J Hematol; 2017 Oct; 92(10):1047-1051. PubMed ID: 28675459
[TBL] [Abstract][Full Text] [Related]
14. Plerixafor: a peripheral blood stem cell mobilizer.
Kessans MR; Gatesman ML; Kockler DR
Pharmacotherapy; 2010 May; 30(5):485-92. PubMed ID: 20411999
[TBL] [Abstract][Full Text] [Related]
15. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide.
Shaughnessy P; Islas-Ohlmayer M; Murphy J; Hougham M; MacPherson J; Winkler K; Silva M; Steinberg M; Matous J; Selvey S; Maris M; McSweeney PA
Biol Blood Marrow Transplant; 2011 May; 17(5):729-36. PubMed ID: 20813198
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II Study of Intravenous Plerixafor Added to a Mobilization Regimen of Granulocyte Colony-Stimulating Factor in Lymphoma Patients Undergoing Autologous Stem Cell Collection.
Cashen AF; Rettig M; Gao F; Smith A; Abboud C; Stockerl-Goldstein K; Vij R; Uy G; Westervelt P; DiPersio J
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1282-1289. PubMed ID: 28476490
[TBL] [Abstract][Full Text] [Related]
17. [Efficiency and safety analysis of Plerixafor combined with granulocyte colony-stimulating factor on autologous hematopoietic stem cell mobilization in lymphoma].
Ji MM; Shen YG; Gong JC; Tang W; Xu XQ; Zheng Z; Chen SY; He Y; Zheng X; Zhao LD; Zhao WL; Wu W
Zhonghua Xue Ye Xue Za Zhi; 2023 Feb; 44(2):112-117. PubMed ID: 36948864
[No Abstract] [Full Text] [Related]
18. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.
DiPersio JF; Micallef IN; Stiff PJ; Bolwell BJ; Maziarz RT; Jacobsen E; Nademanee A; McCarty J; Bridger G; Calandra G;
J Clin Oncol; 2009 Oct; 27(28):4767-73. PubMed ID: 19720922
[TBL] [Abstract][Full Text] [Related]
19. Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure.
Worel N; Fritsch G; Agis H; Böhm A; Engelich G; Leitner GC; Geissler K; Gleixner K; Kalhs P; Buxhofer-Ausch V; Keil F; Kopetzky G; Mayr V; Rabitsch W; Reisner R; Rosskopf K; Ruckser R; Zoghlami C; Zojer N; Greinix HT
J Clin Apher; 2017 Aug; 32(4):224-234. PubMed ID: 27578390
[TBL] [Abstract][Full Text] [Related]
20. Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells.
Basak GW; Jaksic O; Koristek Z; Mikala G; Basic-Kinda S; Mayer J; Masszi T; Giebel S; Labar B; Wiktor-Jedrzejczak W;
Eur J Haematol; 2011 Jun; 86(6):488-95. PubMed ID: 21410533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]